Search - tctmd.com

Displaying 101 - 120 of 163

Sort: Relevancy | Date

News Daily News

Lowering LDL With Statins and Other Selected Agents Should Be Focus of CVD Risk Reduction, Analysis Implies

Michael O'Riordan

September 27, 2016

News Conference News ESC 2016

Ezetimibe Plus Pitavastatin Fails to Lower Risk of CVD Events in ACS Patients: HIJ-PROPER

Michael O'Riordan

August 30, 2016

News Daily News

New PFO Guidelines: No Routine Offer of Closure for Cryptogenic Stroke, Says American Academy of Neurology

Shelley Wood

July 27, 2016

News Daily News

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

Michael O'Riordan

June 30, 2016

News Daily News

FDA 顾问小组小范围建议使用糖尿病药物 empagliflozin 来改善 CVD 死亡率

Michael O'Riordan

June 30, 2016

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

News Daily News

Survey of Interventional Cardiologists With Absorb BVS Expertise Gives Snapshot of Attitudes, Usage

Michael O'Riordan

June 14, 2016

News Daily News

Nestlé Voluntarily Reducing Sodium in Processed Food, but Should the AHA Applaud?

Michael O'Riordan

May 09, 2016

News Daily News

FDA Advisory Committee Rejects AngelMed Guardian Intracardiac Monitor

Todd Neale

March 17, 2016

News Daily News

FDA Panel Overwhelmingly Supports Absorb Bioresorbable Stent

Michael O'Riordan

March 16, 2016

News Daily News

FDA Review of Absorb Bioresorbable Stent Does Not Tip Hand Ahead of Tomorrow’s Advisory Panel Meeting

Michael O'Riordan

March 14, 2016

News Daily News

Will FDA’s Settlement With Amarin Weaken Agency Oversight of Off-Label Promotion?

Michael O'Riordan

March 09, 2016

News Daily News

Cardiologist Robert Califf Becomes New Commissioner of the FDA

L.A. McKeown

February 23, 2016

News Daily News

FDA Advisors Recommend Comprehensive, Long-Term Study of Leadless Pacemakers

Yael L. Maxwell

February 18, 2016

News Daily News

FDA: No Cardiovascular Event Reduction Claim for Ezetimibe

Shelley Wood

February 16, 2016

News Daily News

在他汀类药物治疗基础上添加依泽替米贝可以降低首次和后续心血管事件的风险：IMPROVE-IT 分析

Michael O'Riordan

January 26, 2016

News Daily News

Análisis del IMPROVE-IT: La Incorporación de Ezetimibe al Tratamiento con Estatinas Reduce el Riesgo de Sufrir Primeros y Subsiguientes Episodios CV

Michael O'Riordan

January 26, 2016

News Daily News

Adding Ezetimibe to Statin Therapy Reduces Risk of First and Subsequent CV Events: IMPROVE-IT Analysis

Michael O'Riordan

January 26, 2016

News Daily News

Former FDA Staffer Says Missing Data Across Antithrombotic Trials Cast Doubt on Drug Effects

Shelley Wood

January 18, 2016

News Daily News

Ezetimibe Fails to Garner Support for CV- Event Reduction Claim From FDA Advisory Committee

Michael O'Riordan

December 15, 2015

Advertisement

Lowering LDL With Statins and Other Selected Agents Should Be Focus of CVD Risk Reduction, Analysis Implies

Ezetimibe Plus Pitavastatin Fails to Lower Risk of CVD Events in ACS Patients: HIJ-PROPER

New PFO Guidelines: No Routine Offer of Closure for Cryptogenic Stroke, Says American Academy of Neurology

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

FDA 顾问小组小范围建议使用糖尿病药物 empagliflozin 来改善 CVD 死亡率

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Survey of Interventional Cardiologists With Absorb BVS Expertise Gives Snapshot of Attitudes, Usage

Nestlé Voluntarily Reducing Sodium in Processed Food, but Should the AHA Applaud?

FDA Advisory Committee Rejects AngelMed Guardian Intracardiac Monitor

FDA Panel Overwhelmingly Supports Absorb Bioresorbable Stent

FDA Review of Absorb Bioresorbable Stent Does Not Tip Hand Ahead of Tomorrow’s Advisory Panel Meeting

Will FDA’s Settlement With Amarin Weaken Agency Oversight of Off-Label Promotion?

Cardiologist Robert Califf Becomes New Commissioner of the FDA

FDA Advisors Recommend Comprehensive, Long-Term Study of Leadless Pacemakers

FDA: No Cardiovascular Event Reduction Claim for Ezetimibe

在他汀类药物治疗基础上添加依泽替米贝可以降低首次和后续心血管事件的风险：IMPROVE-IT 分析

Análisis del IMPROVE-IT: La Incorporación de Ezetimibe al Tratamiento con Estatinas Reduce el Riesgo de Sufrir Primeros y Subsiguientes Episodios CV

Adding Ezetimibe to Statin Therapy Reduces Risk of First and Subsequent CV Events: IMPROVE-IT Analysis

Former FDA Staffer Says Missing Data Across Antithrombotic Trials Cast Doubt on Drug Effects

Ezetimibe Fails to Garner Support for CV- Event Reduction Claim From FDA Advisory Committee

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content